AR055361A1 - Inhibidores macrociclicos del virus de la hepatitis c - Google Patents
Inhibidores macrociclicos del virus de la hepatitis cInfo
- Publication number
- AR055361A1 AR055361A1 ARP060103311A ARP060103311A AR055361A1 AR 055361 A1 AR055361 A1 AR 055361A1 AR P060103311 A ARP060103311 A AR P060103311A AR P060103311 A ARP060103311 A AR P060103311A AR 055361 A1 AR055361 A1 AR 055361A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- het
- aryl
- optionally substituted
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 15
- 125000003118 aryl group Chemical group 0.000 abstract 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 9
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 7
- -1 C1-6 polyhaloalkoxy Chemical group 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000006684 polyhaloalkyl group Polymers 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000002757 morpholinyl group Chemical group 0.000 abstract 4
- 125000003386 piperidinyl group Chemical group 0.000 abstract 4
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 4
- 125000004076 pyridyl group Chemical group 0.000 abstract 4
- 125000000335 thiazolyl group Chemical group 0.000 abstract 4
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 239000011593 sulfur Substances 0.000 abstract 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004193 piperazinyl group Chemical group 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005466 alkylenyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicacion 1: Un compuesto que tiene la formula (1), un N-oxido, sal o estereoisomero de éste; donde cada línea de puntos (representada por -------) representa un doble enlace opcional; X es N, CH y cuando X lleva un doble enlace es C; Rla y Rlb son, en forma independiente hidrogeno, cicloalquilo C3-7, arilo, Het, alcoxi C1-6, alquilo C1-6 sustituido en forma opcional con halo, alcoxi C1-6, ciano, polihaloalcoxi C1-6, cicloalquilo C3-7, arilo, o con Het; o Rla y Rlb junto con el nitrogeno al cual están unidos forman una anillo heterocíclico de 4 a 6 miembros, saturado, parcialmente insaturado o completamente insaturado que contiene en forma opcional un adicional de 1 a 3 heteroátomos seleccionados cada uno en forma independiente del nitrogeno, oxígeno y azufre, y donde dicho anillo heterocíclico puede estar sustituido en forma opcional con uno o dos sustituyentes seleccionados, cada uno en forma independiente, del grupo que consiste en halo, alquilo C1-6, polihaloalquilo C1-6, hidroxi, alcoxi C1-6, polihaloalcoxi C1-6, alcoxiC1-6- alquiloC1-6, carboxilo, alquilcarbonilo C1-6, ciano, mono- y dialquilamino C1-6, arilo y arilalquilo C1-6; L es un enlace directo, -O-, - O-alcandiiloC1-4-, -O-CO-, -O-C(=O)-NR5a- u -O-C(=O)- NR5a-alcandiiloC1-4-; R2 es hidrogeno, y cuando X es C o CH, R2 también puede ser alquilo C1-6; R3 es hidrogeno, alquilo C1-6, alcoxiC1-6-alquiloC1-6, cicloalquilo C3-7, amino, mono- o dialquilamino C1-6; R4 es arilo o un sistema anular saturado, parcialmente insaturado o completamente insaturado de 5 o 6 miembros o bicíclico heterocíclico de 9 a 12 miembros donde dicho sistema anular contiene un nitrogeno, y en forma opcional uno a tres heteroátomos adicionales seleccionados del grupo que consiste en oxígeno, azufre y nitrogeno, y donde el resto de los miembros del anillo son átomos de carbono; donde dicho sistema anular puede estar sustituido en forma opcional en cualquier átomo de carbono o nitrogeno del anillo con uno, dos, tres, o cuatro sustituyentes seleccionados cada uno en forma independiente, de cicloalquilo C3-7, arilo, Het, -C(=O)NR5aR5b, - C(=O)R7, -C(=O)OR6a, y alquilo C1-6 sustituido en forma opcional con cicloalquilo C3-7, arilo, Het, - C(=O)NR5aR5b, -NR5aR5b, - C(=O)R7, -NR5aC(=O)R7, -NR5aSOpR8, -SOpR8, -SOpNR5aR5b, -C(=O)OR6, o -NR5aC(O)OR6a y donde los sustituyentes en cada átomo de carbono del anillo heterocíclico pueden seleccionarse, además, de alcoxi C1-6, hidroxi, halo, polihaloalquilo C1-6, alquiltio C1-6, oxo, ciano, nitro, azido, -NR5aR5b, -NR5aC(=O)R7, -NR5aSOpR8, -SOpR8, -SOpNR5aR5b, -O(=O)OH y -NR5aC(=O)OR6a; n es 3, 4, 5, o 6; p es 1 o 2; cada R5a y R5b son, en forma independiente hidrogeno, cicloalquilo C3-7, arilo, Het, alquilo C1-6 sustituido en forma opcional con halo, alcoxi C1-6, ciano, polihaloalcoxi C1-6, cicloalquilo C3-7, arilo, o con Het; R6 es hidrogeno, alquenilo C2-6, cicloalquilo C3-7, Het, o alquilo C1-6 sustituido en forma opcional con cicloalquilo C3-7, arilo o Het; R6a es alquenilo C2-6, cicloalquilo C3-7, Het, alquilo C1-6 sustituido en forma opcional con cicloalquilo C3-7, arilo o Het; R7 es hidrogeno, alquiloC1-6, cicloalquilo C3-7, o arilo; R8 es hidrogeno, polihaloalquilo C1-6, cicloalquilo C3-7, arilo, Het, o alquilo C1-6 sustituido en forma opcional con cicloalquilo C3-7, arilo o Het; arilo como grupo o parte de un grupo es fenilo, naftilo, indanilo, o 1,2,3,4-tetrahidronaftilo, cada uno de los cuales puede estar sustituido en forma opcional con uno, dos o tres sustituyentes seleccionados de halo, alquilo C1-6, polihaloalquilo C1-6, hidroxi, alcoxi C1-6, polihaloalcoxi C1-6, alcoxiC1-6-alquiloC1-6, carboxilo, alquilcarbonilo C1-6, alcoxicarbonilo C1-6, ciano, nitro, amino, mono- o dialquilamino C1-6, aminocarbonilo, mono- o dialquilaminocarbonilo C1-6, azido, mercapto, cicloalquilo C3-7, fenilo, piridilo, tiazolilo, pirazolilo, pirrolidinilo, piperidinilo, piperazinilo, 4-alquilpiperaziniloC1-6, 4-alquilcarbonilC1-6- piperazinilo, y morfolinilo; donde los grupos del morfolinilo y piperidinilo pueden estar sustituidos en forma opcional con uno o dos radicales alquilo C1-6; y los grupos fenilo, piridilo, tiazolilo, pirazolilo pueden estar sustituidos en forma opcional con 1, 2 o 3 sustituyentes seleccionados, cada uno en forma independiente, alquilo C1-6, alcoxi C1-6, halo, amino, mono- o dialquilaminoC1-6; Het como grupo o parte de un grupo es un anillo heterocíclico saturado, parcialmente insaturado o completamente insaturado de 5 o 6 miembros que contiene 1 a 4 heteroátomos seleccionados cada uno en forma independiente de nitrogeno, oxígeno y azufre, condensado en forma opcional con un anillo bencénico, y donde el grupo Het como un todo puede estar sustituido en forma opcional con uno, dos o tres sustituyentes seleccionados, cada uno en forma independiente, del grupo que consiste en halo, alquiloC1-6, polihaloalquilo C1-6, hidroxi, alcoxi C1-6, polihaloalcoxi C1-6, alcoxiC1-6-alquiloC1- 6, carboxilo, alquilcarbonilo C1-6, alcoxicarbonilo C1-6, ciano, nitro, amino, mono- o dialquilaminoC1-6, aminocarbonilo, mono- o dialquilaminocarboniloC1-6, cicloalquilo C3-7, fenilo, piridilo, tiazolilo, pirazolilo, pirrolidinilo, piperidinilo, piperazinilo, 4-alquilpiperaziniloC1-6, 4-alquilcarbonilC1-6-piperazinilo, y morfolinilo; donde los grupos morfolinilo y piperidinilo pueden estar sustituidos en forma opcional con uno o dos radicales alquilo C1-6; y los grupos fenilo, piridilo, tiazolilo, pirazolilo pueden estar sustituidos en forma opcional con 1, 2 o 3 sustituyentes seleccionados, cada uno en forma independiente, de alquilo C1-6, alcoxi C1-6, halo, amino, mono- o dialquilaminoC1-6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05107073 | 2005-07-29 | ||
| EP05107416 | 2005-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055361A1 true AR055361A1 (es) | 2007-08-22 |
Family
ID=37032218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103311A AR055361A1 (es) | 2005-07-29 | 2006-07-28 | Inhibidores macrociclicos del virus de la hepatitis c |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8227407B2 (es) |
| EP (1) | EP1912997B1 (es) |
| JP (1) | JP5230417B2 (es) |
| CN (1) | CN101282978B (es) |
| AR (1) | AR055361A1 (es) |
| AT (1) | ATE524475T1 (es) |
| BR (1) | BRPI0614637A2 (es) |
| CY (1) | CY1112147T1 (es) |
| DK (1) | DK1912997T3 (es) |
| ES (1) | ES2373685T3 (es) |
| HR (1) | HRP20110885T1 (es) |
| ME (1) | ME01318B (es) |
| MY (1) | MY139923A (es) |
| PL (1) | PL1912997T3 (es) |
| PT (1) | PT1912997E (es) |
| RS (1) | RS52058B (es) |
| SI (1) | SI1912997T1 (es) |
| TW (1) | TW200745061A (es) |
| WO (1) | WO2007014925A1 (es) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| CA2552319C (en) | 2004-01-30 | 2012-08-21 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| WO2007014922A1 (en) * | 2005-07-29 | 2007-02-08 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
| RU2437886C2 (ru) * | 2005-07-29 | 2011-12-27 | Тиботек Фармасьютикалз Лтд. | Макроциклические ингибиторы вируса гепатита с |
| DK1913015T3 (en) | 2005-07-29 | 2014-03-10 | Janssen R & D Ireland | Macrocyclic inhibitors of hepatitis C virus |
| ME01318B (me) | 2005-07-29 | 2013-12-20 | Tibotec Pharm Ltd | Makrociklički inhibitori virusa hepatitisa C |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EA200970493A1 (ru) | 2006-11-17 | 2009-10-30 | Тиботек Фармасьютикалз Лтд. | Макроциклические ингибиторы вируса гепатита с |
| MX2009008540A (es) | 2007-02-08 | 2009-08-18 | Tibotec Pharm Ltd | Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina. |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| AP2009005053A0 (en) * | 2007-05-03 | 2009-12-31 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
| KR20100027134A (ko) | 2007-05-10 | 2010-03-10 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 펩티드 억제제 |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| MX2010005261A (es) | 2007-11-14 | 2010-10-15 | Enanta Pharm Inc | Inhibidores macrocíclicos de proteasa de serina de hepatitis c de tetrazolilo. |
| US8273709B2 (en) | 2007-12-14 | 2012-09-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic HCV serine protease inhibitors |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| JP5574982B2 (ja) * | 2008-02-04 | 2014-08-20 | イデニク プハルマセウティカルス，インコーポレイテッド | 大環状セリンプロテアーゼ阻害剤 |
| MX2010010276A (es) | 2008-03-20 | 2011-03-25 | Enanta Pharm Inc | Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c. |
| WO2009142842A2 (en) * | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5529120B2 (ja) | 2008-05-29 | 2014-06-25 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎ウイルス阻害剤 |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2746834A1 (en) * | 2008-12-22 | 2010-07-01 | Gilead Sciences, Inc. | Antiviral compounds |
| US8716263B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| EA019341B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Фосфорамидаты нуклеозидов |
| EA201100851A1 (ru) | 2008-12-23 | 2012-04-30 | Фармассет, Инк. | Аналоги нуклеозидов |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| EP2403860B1 (en) | 2009-03-04 | 2015-11-04 | IDENIX Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole as hcv polymerase inhibitors |
| EP2417134B1 (en) | 2009-04-08 | 2017-05-17 | Idenix Pharmaceuticals LLC. | Macrocyclic serine protease inhibitors |
| TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TW201117812A (en) | 2009-08-05 | 2011-06-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| KR20130026410A (en) * | 2009-09-28 | 2013-03-13 | Intermune Inc | Cyclic peptide inhibitors of hepatitis c virus replication |
| WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
| KR20120118008A (ko) | 2009-12-18 | 2012-10-25 | 아이데닉스 파마슈티칼스, 인코포레이티드 | 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제 |
| MX2012011171A (es) | 2010-03-31 | 2013-02-01 | Gilead Pharmasset Llc | Fosforamidatos de nucleosido. |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| UY33312A (es) | 2010-03-31 | 2011-10-31 | Pharmasset Inc | Fosforamidato de nucleosido de purina |
| US20160038600A1 (en) | 2012-08-03 | 2016-02-11 | Neonc Technologies Inc. | Pharmaceutical compositions comprising poh derivatives |
| JP6069215B2 (ja) | 2010-11-30 | 2017-02-01 | ギリアド ファーマセット エルエルシー | 化合物 |
| BR112013015107B1 (pt) * | 2010-12-17 | 2022-03-22 | Neonc Technologies Inc. | Composição farmacêutica, uso de um álcool isoperílico ou um carbamato de álcool isoper ílico e processo para produzir um carbamato de álcool isoperílico |
| WO2012092409A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Phararmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
| CA2821340A1 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc. | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
| TW201309690A (zh) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途 |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| SG11201400664WA (en) | 2011-09-16 | 2014-04-28 | Gilead Pharmassett Llc | Methods for treating hcv |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| SG11201502802PA (en) | 2012-10-19 | 2015-05-28 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US20140212491A1 (en) | 2013-01-31 | 2014-07-31 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| CN105164148A (zh) | 2013-03-07 | 2015-12-16 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| EP3038601B1 (en) | 2013-08-27 | 2020-04-08 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| EP3046924A1 (en) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
| ES2846833T3 (es) | 2016-07-18 | 2021-07-29 | Janssen Pharmaceutica Nv | Ligandos de obtención de imágenes de tau por PET |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0727419B1 (en) | 1992-12-29 | 2002-02-27 | Abbott Laboratories | Intermediates for the preparation of retroviral protease inhibiting compounds |
| IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| PL192628B1 (pl) | 1996-04-23 | 2006-11-30 | Vertex Pharma | Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji |
| UA66767C2 (uk) | 1996-10-18 | 2004-06-15 | Вертекс Фармасьютикалс Інкорпорейтед | Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| EP0966465B1 (en) | 1997-03-14 | 2003-07-09 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
| AU757072B2 (en) | 1997-08-11 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptide analogues |
| US6075150A (en) | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| ES2405316T3 (es) | 1999-03-19 | 2013-05-30 | Vertex Pharmaceuticals Incorporated | Inhibidores de la enzima IMPDH |
| UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| CA2383603A1 (en) | 1999-08-31 | 2001-03-08 | Neil R. Taylor | Method of identifying inhibitors of cdc25 |
| FR2803203B1 (fr) | 1999-12-31 | 2002-05-10 | Fournier Ind & Sante | Nouvelles formulations galeniques du fenofibrate |
| ES2240446T3 (es) | 2000-04-03 | 2005-10-16 | Vertex Pharma | Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c. |
| CN102206247B (zh) | 2000-07-21 | 2013-03-27 | 默沙东公司 | 一种具有HCV NS3/NS4a蛋白酶抑制活性的化合物 |
| AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
| AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| AU2002227984B8 (en) | 2000-12-18 | 2007-01-04 | Actelion Pharmaceuticals Ltd. | Novel sulfamides and their use as endothelin receptor antagonists |
| WO2003006490A1 (en) | 2001-07-11 | 2003-01-23 | Vertex Pharmaceuticals Incorporated | Bridged bicyclic serine protease inhibitors |
| US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| MXPA04009938A (es) | 2002-04-11 | 2004-12-13 | Vertex Pharma | Inhibidores de serina proteasas, en particular la proteasa ns3-ns4a del hcv. |
| US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| AU2004211637C1 (en) | 2003-02-07 | 2010-08-19 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
| JP4733023B2 (ja) * | 2003-04-16 | 2011-07-27 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤 |
| US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| DE602004031645D1 (de) * | 2003-09-22 | 2011-04-14 | Boehringer Ingelheim Pharma | Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus |
| US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2552319C (en) * | 2004-01-30 | 2012-08-21 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
| DK1919899T3 (da) | 2005-07-29 | 2011-08-01 | Tibotec Pharm Ltd | Makrocykliske inhibitorer af hepatitis C virus |
| RU2437886C2 (ru) * | 2005-07-29 | 2011-12-27 | Тиботек Фармасьютикалз Лтд. | Макроциклические ингибиторы вируса гепатита с |
| US7700552B2 (en) * | 2005-07-29 | 2010-04-20 | Medivir Ab | Macrocyclic inhibitors of hepatitis C virus |
| DK1912996T3 (da) * | 2005-07-29 | 2012-09-17 | Janssen R & D Ireland | Makrocykliske inhibitorer af hepatitis C-virus |
| DK1913015T3 (en) | 2005-07-29 | 2014-03-10 | Janssen R & D Ireland | Macrocyclic inhibitors of hepatitis C virus |
| WO2007014922A1 (en) | 2005-07-29 | 2007-02-08 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
| ME01318B (me) | 2005-07-29 | 2013-12-20 | Tibotec Pharm Ltd | Makrociklički inhibitori virusa hepatitisa C |
| PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
| PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
-
2006
- 2006-07-28 ME MEP-2011-194A patent/ME01318B/me unknown
- 2006-07-28 PL PL06764267T patent/PL1912997T3/pl unknown
- 2006-07-28 WO PCT/EP2006/064819 patent/WO2007014925A1/en not_active Ceased
- 2006-07-28 SI SI200631188T patent/SI1912997T1/sl unknown
- 2006-07-28 RS RS20110542A patent/RS52058B/sr unknown
- 2006-07-28 BR BRPI0614637-6A patent/BRPI0614637A2/pt not_active Application Discontinuation
- 2006-07-28 EP EP06764267A patent/EP1912997B1/en active Active
- 2006-07-28 MY MYPI20063665A patent/MY139923A/en unknown
- 2006-07-28 PT PT06764267T patent/PT1912997E/pt unknown
- 2006-07-28 DK DK06764267.8T patent/DK1912997T3/da active
- 2006-07-28 JP JP2008523381A patent/JP5230417B2/ja not_active Expired - Fee Related
- 2006-07-28 AR ARP060103311A patent/AR055361A1/es unknown
- 2006-07-28 TW TW095127591A patent/TW200745061A/zh unknown
- 2006-07-28 ES ES06764267T patent/ES2373685T3/es active Active
- 2006-07-28 HR HR20110885T patent/HRP20110885T1/hr unknown
- 2006-07-28 CN CN2006800350583A patent/CN101282978B/zh not_active Expired - Fee Related
- 2006-07-28 AT AT06764267T patent/ATE524475T1/de active
-
2008
- 2008-01-16 US US11/995,835 patent/US8227407B2/en not_active Expired - Fee Related
-
2011
- 2011-12-14 CY CY20111101239T patent/CY1112147T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20110885T1 (hr) | 2011-12-31 |
| ES2373685T3 (es) | 2012-02-07 |
| CY1112147T1 (el) | 2015-11-04 |
| RS52058B (sr) | 2012-04-30 |
| US20090062311A1 (en) | 2009-03-05 |
| ME01318B (me) | 2013-12-20 |
| PT1912997E (pt) | 2011-12-19 |
| RU2008107768A (ru) | 2009-09-10 |
| SI1912997T1 (sl) | 2012-02-29 |
| TW200745061A (en) | 2007-12-16 |
| PL1912997T3 (pl) | 2012-02-29 |
| BRPI0614637A2 (pt) | 2011-04-12 |
| EP1912997A1 (en) | 2008-04-23 |
| DK1912997T3 (da) | 2012-01-02 |
| JP5230417B2 (ja) | 2013-07-10 |
| WO2007014925A1 (en) | 2007-02-08 |
| CN101282978B (zh) | 2012-07-11 |
| JP2009502888A (ja) | 2009-01-29 |
| MY139923A (en) | 2009-11-30 |
| US8227407B2 (en) | 2012-07-24 |
| CN101282978A (zh) | 2008-10-08 |
| EP1912997B1 (en) | 2011-09-14 |
| ATE524475T1 (de) | 2011-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR055361A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| AR055104A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| AR057703A1 (es) | INHIBIDORES MACROCíCLICOS DEL VIRUS DE LA HEPATITIS C. PROCESO DE PREPARACIoN Y COMPOSICIONES FARMACÉUTICAS. | |
| AR057704A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c, composicion farmaceutica y proceso de preparacion del compuesto | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| AR055360A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| CO5680432A2 (es) | Pirimidinilaminobenzamidas sustituidas como inhibidores de cinasas de tirosina | |
| AR055359A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| AR055105A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| ECSP066780A (es) | Inhibidores de polimerasa viral | |
| CO5580824A2 (es) | Derivados de fenil o heteroaril amino alcano como antagonis- tas del receptor ip | |
| EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| AR086019A1 (es) | COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS | |
| AR038703A1 (es) | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 | |
| AR067327A1 (es) | Derivados de piperidina / piperazina | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| CY1114319T1 (el) | Νεες υδροξυ-6-ετεροαρυλφαινανθριδινες και χρηση αυτων ως αναστολεις pde4 | |
| AR054882A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| ES2722409T3 (es) | Moduladores de ROR gamma (RORy) | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| CO6321244A2 (es) | Pirrolopiridinas como inhibidores de cinasa | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| SA520411638B1 (ar) | Tam أملاح لمشتقات بيرولو ترايازين مفيدة كمثبطات لـ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |